Verona Makes Strides With Niche Two-In-One COPD Treatment
This article was originally published in Scrip
Executive Summary
Verona Pharma's dual-acting novel therapy for chronic obstructive pulmonary disease (COPD) RPL554 has matched the bronchodilatory effects of salbutamol with fewer side-effects in a Phase IIa study, top-line data show.